TCRR - TCR2 Therapeutics Inc.
| Previous Close | 14.52 |
| Open | 14.64 |
| Bid | 0.00 x 1300 |
| Ask | 0.00 x 1400 |
| Day's Range | 14.55 - 15.31 |
| 52 Week Range | 10.04 - 25.47 |
| Volume | 70,410 |
| Avg. Volume | 96,107 |
| Market Cap | 354.502M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -6.29 |
| Earnings Date | Nov 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 25.50 |
- GlobeNewswire
TCR² Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 07, 2020 -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for.
- Insider Monkey
Is TCR2 Therapeutics Inc. (TCRR) A Good Stock To Buy ?
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]
- GlobeNewswire
TCR² Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass., Nov. 12, 2019 -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for.
- Simply Wall St.
TCR2 Therapeutics (NASDAQ:TCRR) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
- GlobeNewswire
Tcr² Therapeutics Appoints Industry Veteran Angela Justice, Ph.D., as Chief People Officer
TCR2 Therapeutics Inc. (TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced the appointment of Angela Justice, Ph.D., as its first Chief People Officer. “We are delighted to announce the appointment of Angela to the TCR2 executive team,” said Garry Menzel, Ph.D., President and Chief Executive Officer of TCR2 Therapeutics. Over the course of her career, Angela has consistently focused on improving the employee experience by providing clarity of purpose, measurable metrics and resources for continuous learning.
- GlobeNewswire
TCR² Therapeutics to Present at the Cantor Global Healthcare Conference
CAMBRIDGE, Mass., Sept. 27, 2019 -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for.
- Zacks
TCR2 Therapeutics Sees Hammer Chart Pattern: Time to Buy?
TCR2 Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.
- GlobeNewswire
TCR² Therapeutics to Present at the BioCentury NewsMakers in the Biotech Industry Conference
CAMBRIDGE, Mass., Aug. 30, 2019 -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for.
- Simply Wall St.
How Much Of TCR2 Therapeutics Inc. (NASDAQ:TCRR) Do Institutions Own?
If you want to know who really controls TCR2 Therapeutics Inc. (NASDAQ:TCRR), then you'll have to look at the makeup...
- Zacks
TCR2 Therapeutics Inc. (TCRR) Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in TCR2 Therapeutics Inc. (TCRR).
- GlobeNewswire
TCR² Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Began dosing of TC-210 in the Phase 1/2 trial for patients with mesothelin-expressing solid tumors and an interim update anticipated in 4Q19/1Q20Leading clinical sites.
- GlobeNewswire
TCR² Therapeutics to Participate in Upcoming Conferences in August
CAMBRIDGE, Mass., Aug. 06, 2019 -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for.
- GlobeNewswire
TCR2 Therapeutics Deepens Manufacturing and Immuno-Oncology Expertise with Key Hires
TCR2 Therapeutics Inc. (TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced an expansion of its leadership team to strengthen expertise in manufacturing, Investigational New Drug (IND) enablement and innovation as the Company advances its approach of creating next generation TRuCTM-T cells addressing the tumor microenvironment. “It is a pleasure to expand our leadership team with experts that deepen three core TCR2 competencies – manufacturing, IND enablement and innovation,” said Garry Menzel, Ph.D., President and Chief Executive Officer of TCR2 Therapeutics.
- GlobeNewswire
TCR2 Therapeutics Announces Partnership with the National Cancer Institute for Phase 1/2 Trial of TC-210
TCR2 Therapeutics Inc. (TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to collaborate on the use of TCR2’s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuCTM-T cells) as a cancer therapeutic agent against mesothelin in the Company’s ongoing Phase 1/2 trial of TC-210. The collaboration with the Thoracic and GI Malignancies Branch (TGMB) at NCI, led by Raffit Hassan, M.D., provides TCR2 with access to Dr. Hassan and TGMB’s extensive laboratory and clinical expertise for treating patients with advanced mesothelin-expressing cancers.
- GlobeNewswire
TCR2 Therapeutics Added to Russell 2000®, 3000® and Microcap® Indexes
CAMBRIDGE, Mass., June 28, 2019 -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for.
- Simply Wall St.
Who Has Been Buying TCR2 Therapeutics Inc. (NASDAQ:TCRR) Shares?
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...
Motley FoolTCR2 Therapeutics Inc. (TCRR) Q1 2019 Earnings Call Transcript
TCRR earnings call for the period ending March 31, 2019.
- GlobeNewswire
TCR2 Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
Initiated Phase 1/2 clinical trial for TC-210, TCR2’s lead product candidate targeting mesothelin expressing solid tumorsOn track to file an IND for TCR2’s lead hematology.
- GlobeNewswire
TCR2 Therapeutics Publishes First Peer-Reviewed Data Demonstrating Superior Anti-Tumor Activity of the Company’s Novel TRuC™-T Cells
TCR2 Therapeutics Inc. (TCR2) (TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced online publication of preclinical data in Nature Communications (https://www/nature.com/articles/s41467-019-10097-0). The paper is entitled, “Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response,” and shows in several mouse models a higher anti-tumor activity of the company’s proprietary T cell receptor (TCR) fusion construct T cells (TRuC™)-T cells compared to chimeric antigen receptor (CAR)-T cells.
- GlobeNewswire
TCR2 Therapeutics Announces First Quarter 2019 Earnings Conference Call and Webcast
Earnings to be released after market close on Monday, May 13, 2019 CAMBRIDGE, Mass., April 29, 2019 -- TCR2 Therapeutics Inc. (TCR2) (Nasdaq: TCRR), a clinical-stage.
- PR Newswire
TCR2 Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
- U.S. Food and Drug Administration (FDA) cleared TCR2's investigational new drug (IND) application for its lead solid tumor candidate TC-210; Company initiated Phase 1/2 clinical trial - Initial public ...
- PR Newswire
TCR2 Therapeutics Presents Preclinical Data on its Lead Solid Tumor and Blood Cancer Programs at the American Association for Cancer Research (AACR) Annual Meeting
CAMBRIDGE, Mass. , March 28, 2019 /PRNewswire/ -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell receptor (TCR) therapies ...
- PR Newswire
TCR2 Therapeutics Announces Collaboration With Cell and Gene Therapy Catapult for the Manufacturing of its Novel T Cell Therapies for Cancer
CAMBRIDGE, Mass. and LONDON, March 26, 2019 /PRNewswire/ -- TCR2 Therapeutics Inc. (TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell receptor (TCR) therapies for patients suffering from cancer, today announced it has selected the advanced therapy medicinal products (ATMP) ecosystem in the United Kingdom (UK) to establish a site for global manufacturing systems and capabilities. TCR2 will work with Cell and Gene Therapy Catapult (CGT Catapult) at their Stevenage manufacturing center to produce its novel TCR therapies based on the company's proprietary TRuC™ (TCR Fusion Construct) T cells.
- PR Newswire
TCR2 Therapeutics Announces Exercise of Over-Allotment Option
CAMBRIDGE, Mass., Feb. 26, 2019 /PRNewswire/ -- TCR2 Therapeutics Inc. (TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell receptor (TCR) therapies for patients suffering from cancer, today announced that the underwriters of its recent initial public offering of common stock have exercised in full their over-allotment option and purchased an additional 750,000 shares at $15.00 per share, before deducting underwriting discounts and commissions. On February 13, 2019, TCR2 priced its initial public offering of 5,000,000 shares of common stock at $15.00 per share.
